RxDoctor Payments Data

Tyler Coakley

Primary Care · Bel Air, MDNPI 1679347546

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 27 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 8 manufacturers reported payments, led by Exact Sciences at 29.3% of the total.

$798in general payments, 2019–2025

Across 27 payments — averaging $29.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Exact Sciences$234
  • AstraZeneca$152
  • Pfizer$149
  • AbbVie$108
  • Lilly USA, LLC$81
  • Amgen$34
  • plus $40 from 2 others

What the payments were for

  • Food & beverage$798100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Exact Sciences6$234
AstraZeneca7$152
Pfizer5$149
AbbVie2$108
Lilly USA, LLC4$81
Amgen1$34
Novo Nordisk1$22
The Binding Site Inc.1$19

How this compares

$798 in reported general payments places this provider in the 65th percentile of 191 primary care providers in Maryland.

See all primary care providers in Maryland

Medicare billing

Part B allowed, 2024
$34,555
Medicare patients
206
Services billed
471

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban11$11,966
Rosuvastatin Calcium68$1,093
Atorvastatin Calcium62$746
Losartan Potassium44$698
Levothyroxine Sodium50$494
Metoprolol Succinate23$424
Ezetimibe11$422
Amlodipine Besylate38$366
Metformin Hcl16$292
Montelukast Sodium14$238
Metformin Hcl ErMetformin Hcl14$215
Albuterol Sulfate HfaAlbuterol Sulfate14$209
Fluticasone Propionate21$208
Alprazolam47$206
Omeprazole12$194

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$149$11,96611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 191 primary care providers in Maryland.

Other primary care in Bel Air

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →